[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEclDlefOQ6gKNbSSCjMv_T5vVctV_kGr9VOxqJvzWl8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":8,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":66,"rows":73},"JW Pharmaceutical",[4],77,false,7,16,60744,14,[13,16,18,21,24,27,29,32],{"name":14,"count":15},"Healthy",18,{"name":17,"count":8},"Hypercholesterolemia",{"name":19,"count":20},"Type 2 Diabetes Mellitus",6,{"name":22,"count":23},"Hypertension",5,{"name":25,"count":26},"Dyslipidemia",4,{"name":28,"count":26},"Gout",{"name":30,"count":31},"Benign Prostatic Hyperplasia",3,{"name":33,"count":34},"Acute Myocardial Infarction",2,[36,41,46,51,56,61],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06703710","To Evaluate the Safety\u002FTolerability and Pharmacokinetic Characteristics in Healthy Volunteers","2025-11","JW2286",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07442630","Long-term Comparison of Pitavastatin\u002FEzetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","2026-01-22","Pitavastatin 4mg",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06643130","Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","2026-04","JW0104+C2402",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07514780","To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers","2026-12-31","JW0061 SAD",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07442006","Glycemic Variability of Combination Therapies in T2DM","2027-03-31","Empagliflozin\u002FMetformin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07378098","to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","2028-03-31","KLH-2109+ Leurprorelin acetate Placebo",[67,68,69,70,71,72],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[74,99,124,142,160,210,237,261,279,301,319,337,358,380,398,466,503,529,556,574,600,618,642,660,686,711,764,801,823,857,879,904,929,947,965,983,1001,1019,1037,1055,1073,1091,1116,1140,1166,1184,1210,1228,1253,1271,1295,1350,1407,1429,1467,1496,1514,1532,1550,1568,1596,1614,1632,1650,1674,1692,1737,1774,1792,1821,1839,1857,1875,1893,1918,1945,1963,1981,2005,2034,2052,2070,2088,2106,2124,2147,2165,2191,2209,2227,2257,2275,2293,2311,2329,2347,2365,2383,2409,2427,2445,2469,2487,2541],{"intervention":75,"totalTrials":76,"cells":77},"Ezetimibe 10 mg",1,{"EARLY_PHASE1":78,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":97},{"trials":79,"activeCount":80},[],0,{"trials":82,"activeCount":80},[],{"trials":84,"activeCount":80},[],{"trials":86,"activeCount":80},[],{"trials":88,"activeCount":76,"soonestReadout":44},[89],{"nctId":42,"briefTitle":43,"status":90,"phases":91,"primaryCompletion":44,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":96},"ACTIVE_NOT_RECRUITING",[71],"2026-11-30","2023-08-21",88,[17],[45,75],{"trials":98,"activeCount":80},[],{"intervention":60,"totalTrials":76,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":122},{"trials":102,"activeCount":80},[],{"trials":104,"activeCount":80},[],{"trials":106,"activeCount":80},[],{"trials":108,"activeCount":80},[],{"trials":110,"activeCount":76,"soonestReadout":59},[111],{"nctId":57,"briefTitle":58,"status":112,"phases":113,"primaryCompletion":59,"completion":59,"start":114,"enrollment":115,"conditions":116,"interventions":118},"RECRUITING",[71],"2025-10-29",178,[117],"Type 2 Diabetes Mellitus (T2DM)",[60,119,120,121],"Anagliptin","Metformin","Empagliflozin\u002FLinagliptin",{"trials":123,"activeCount":80},[],{"intervention":120,"totalTrials":76,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":80},[],{"trials":129,"activeCount":80},[],{"trials":131,"activeCount":80},[],{"trials":133,"activeCount":80},[],{"trials":135,"activeCount":76,"soonestReadout":59},[136],{"nctId":57,"briefTitle":58,"status":112,"phases":137,"primaryCompletion":59,"completion":59,"start":114,"enrollment":115,"conditions":138,"interventions":139},[71],[117],[60,119,120,121],{"trials":141,"activeCount":80},[],{"intervention":121,"totalTrials":76,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":158},{"trials":145,"activeCount":80},[],{"trials":147,"activeCount":80},[],{"trials":149,"activeCount":80},[],{"trials":151,"activeCount":80},[],{"trials":153,"activeCount":76,"soonestReadout":59},[154],{"nctId":57,"briefTitle":58,"status":112,"phases":155,"primaryCompletion":59,"completion":59,"start":114,"enrollment":115,"conditions":156,"interventions":157},[71],[117],[60,119,120,121],{"trials":159,"activeCount":80},[],{"intervention":119,"totalTrials":26,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":191,"NA":197},{"trials":163,"activeCount":80},[],{"trials":165,"activeCount":80},[],{"trials":167,"activeCount":80},[],{"trials":169,"activeCount":80},[170,181],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT01529528","A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients","COMPLETED",[70],"2012-09","2012-11","2011-05",117,[19],[119,119],{"nctId":182,"briefTitle":183,"status":173,"phases":184,"primaryCompletion":185,"completion":186,"start":177,"enrollment":187,"conditions":188,"interventions":189},"NCT01529541","Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone",[70],"2013-05","2013-10",200,[19],[119,190],"Sitagliptin",{"trials":192,"activeCount":76,"soonestReadout":59},[193],{"nctId":57,"briefTitle":58,"status":112,"phases":194,"primaryCompletion":59,"completion":59,"start":114,"enrollment":115,"conditions":195,"interventions":196},[71],[117],[60,119,120,121],{"trials":198,"activeCount":80},[199],{"nctId":200,"briefTitle":201,"status":202,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT04267601","Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM","UNKNOWN",[],"2021-03-30","2021-09-30","2017-07-06",2448,[19],[119],{"intervention":45,"totalTrials":34,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":226},{"trials":213,"activeCount":80},[],{"trials":215,"activeCount":80},[],{"trials":217,"activeCount":80},[],{"trials":219,"activeCount":80},[],{"trials":221,"activeCount":76,"soonestReadout":44},[222],{"nctId":42,"briefTitle":43,"status":90,"phases":223,"primaryCompletion":44,"completion":92,"start":93,"enrollment":94,"conditions":224,"interventions":225},[71],[17],[45,75],{"trials":227,"activeCount":80},[228],{"nctId":229,"briefTitle":230,"status":202,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT04270344","The Occurrence of MACE in Patients With AMI Receiving Pitavastatin\u002FValsartan Treatment",[],"2022-06-30","2018-07-01",905,[17],[45],{"intervention":65,"totalTrials":76,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":257,"NA":259},{"trials":240,"activeCount":80},[],{"trials":242,"activeCount":80},[],{"trials":244,"activeCount":80},[],{"trials":246,"activeCount":76,"soonestReadout":64},[247],{"nctId":62,"briefTitle":63,"status":112,"phases":248,"primaryCompletion":64,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},[70],"2028-09-03","2026-02-03",254,[253,254],"Menorrhagia","Uterine Fibroids",[65,256],"KLH-2109 Placebo + Leurprorelin acetate",{"trials":258,"activeCount":80},[],{"trials":260,"activeCount":80},[],{"intervention":256,"totalTrials":76,"cells":262},{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":275,"NA":277},{"trials":264,"activeCount":80},[],{"trials":266,"activeCount":80},[],{"trials":268,"activeCount":80},[],{"trials":270,"activeCount":76,"soonestReadout":64},[271],{"nctId":62,"briefTitle":63,"status":112,"phases":272,"primaryCompletion":64,"completion":249,"start":250,"enrollment":251,"conditions":273,"interventions":274},[70],[253,254],[65,256],{"trials":276,"activeCount":80},[],{"trials":278,"activeCount":80},[],{"intervention":50,"totalTrials":76,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":297,"NA":299},{"trials":282,"activeCount":80},[],{"trials":284,"activeCount":80},[],{"trials":286,"activeCount":80},[],{"trials":288,"activeCount":76,"soonestReadout":49},[289],{"nctId":47,"briefTitle":48,"status":112,"phases":290,"primaryCompletion":49,"completion":49,"start":291,"enrollment":292,"conditions":293,"interventions":294},[70],"2024-12-02",162,[22,25],[50,295,296],"JW0104+C2403","C2402",{"trials":298,"activeCount":80},[],{"trials":300,"activeCount":80},[],{"intervention":295,"totalTrials":76,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":315,"NA":317},{"trials":304,"activeCount":80},[],{"trials":306,"activeCount":80},[],{"trials":308,"activeCount":80},[],{"trials":310,"activeCount":76,"soonestReadout":49},[311],{"nctId":47,"briefTitle":48,"status":112,"phases":312,"primaryCompletion":49,"completion":49,"start":291,"enrollment":292,"conditions":313,"interventions":314},[70],[22,25],[50,295,296],{"trials":316,"activeCount":80},[],{"trials":318,"activeCount":80},[],{"intervention":296,"totalTrials":76,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":333,"NA":335},{"trials":322,"activeCount":80},[],{"trials":324,"activeCount":80},[],{"trials":326,"activeCount":80},[],{"trials":328,"activeCount":76,"soonestReadout":49},[329],{"nctId":47,"briefTitle":48,"status":112,"phases":330,"primaryCompletion":49,"completion":49,"start":291,"enrollment":292,"conditions":331,"interventions":332},[70],[22,25],[50,295,296],{"trials":334,"activeCount":80},[],{"trials":336,"activeCount":80},[],{"intervention":40,"totalTrials":76,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":350,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":340,"activeCount":80},[],{"trials":342,"activeCount":76,"soonestReadout":39},[343],{"nctId":37,"briefTitle":38,"status":112,"phases":344,"primaryCompletion":39,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":349},[68],"2026-01","2025-01-06",72,[14],[40],{"trials":351,"activeCount":80},[],{"trials":353,"activeCount":80},[],{"trials":355,"activeCount":80},[],{"trials":357,"activeCount":80},[],{"intervention":55,"totalTrials":76,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":361,"activeCount":80},[],{"trials":363,"activeCount":76,"soonestReadout":54},[364],{"nctId":52,"briefTitle":53,"status":112,"phases":365,"primaryCompletion":54,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},[68],"2027-04-30","2026-04-13",104,[14],[55,371],"JW0061 MAD",{"trials":373,"activeCount":80},[],{"trials":375,"activeCount":80},[],{"trials":377,"activeCount":80},[],{"trials":379,"activeCount":80},[],{"intervention":371,"totalTrials":76,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":383,"activeCount":80},[],{"trials":385,"activeCount":76,"soonestReadout":54},[386],{"nctId":52,"briefTitle":53,"status":112,"phases":387,"primaryCompletion":54,"completion":366,"start":367,"enrollment":368,"conditions":388,"interventions":389},[68],[14],[55,371],{"trials":391,"activeCount":80},[],{"trials":393,"activeCount":80},[],{"trials":395,"activeCount":80},[],{"trials":397,"activeCount":80},[],{"intervention":399,"totalTrials":23,"cells":400},"Silodosin",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":464},{"trials":402,"activeCount":80},[],{"trials":404,"activeCount":80},[],{"trials":406,"activeCount":80},[],{"trials":408,"activeCount":80},[],{"trials":410,"activeCount":80},[411,423,434,444,455],{"nctId":412,"briefTitle":413,"status":173,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":421},"NCT01228370","Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder",[71],"2012-01","2011-04",95,[419,420],"Neurogenic Bladder","Voiding Dysfunction",[422],"silodosin",{"nctId":424,"briefTitle":425,"status":173,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT01533389","Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones",[71],"2012-03","2012-08","2011-10",114,[432],"Ureteral Stone",[399],{"nctId":435,"briefTitle":436,"status":173,"phases":437,"primaryCompletion":438,"completion":429,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT01260129","Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH",[71],"2010-11","2010-10",424,[442],"Benign Prostatic Hypertrophy",[399,399],{"nctId":445,"briefTitle":446,"status":173,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT02106182","Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia",[71],"2016-03-02","2016-08-01","2014-01-02",135,[453,30],"Nocturia",[399],{"nctId":456,"briefTitle":457,"status":173,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":463},"NCT01259531","Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)",[71],"2011-09","2010-12",100,[30],[399],{"trials":465,"activeCount":80},[],{"intervention":467,"totalTrials":34,"cells":468},"Atorvastatin",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":501},{"trials":470,"activeCount":80},[],{"trials":472,"activeCount":80},[],{"trials":474,"activeCount":80},[],{"trials":476,"activeCount":80},[],{"trials":478,"activeCount":80},[479,491],{"nctId":480,"briefTitle":481,"status":173,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT00889226","Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia",[71],"2009-05","2010-01","2008-04",161,[488],"Hypercholesterolemia With Type2DM",[490,467],"Pitavastatin",{"nctId":492,"briefTitle":493,"status":173,"phases":494,"primaryCompletion":438,"completion":495,"start":496,"enrollment":187,"conditions":497,"interventions":498},"NCT01166633","Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia",[71],"2011-02","2009-06",[17],[499,500],"pitavastatin","atorvastatin",{"trials":502,"activeCount":80},[],{"intervention":504,"totalTrials":76,"cells":505},"Anagliptin BID Treatment",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":527},{"trials":507,"activeCount":80},[],{"trials":509,"activeCount":80},[],{"trials":511,"activeCount":80},[],{"trials":513,"activeCount":80},[],{"trials":515,"activeCount":80},[516],{"nctId":517,"briefTitle":518,"status":173,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT04810507","MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus",[71],"2020-09-02","2021-01-05","2018-11-09",89,[525],"Type 2 Diabetes",[504],{"trials":528,"activeCount":80},[],{"intervention":530,"totalTrials":76,"cells":531},"Mitiglinide",{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":540,"NA":554},{"trials":533,"activeCount":80},[],{"trials":535,"activeCount":80},[],{"trials":537,"activeCount":80},[],{"trials":539,"activeCount":80},[],{"trials":541,"activeCount":80},[542],{"nctId":543,"briefTitle":544,"status":173,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT00663884","Glufast On Insulin Glargine Trial in Type 2 DM",[71],"2009-07","2009-09","2008-02",167,[551],"Diabetes Mellitus, Type 2",[530,553],"Voglibose",{"trials":555,"activeCount":80},[],{"intervention":553,"totalTrials":76,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":572},{"trials":559,"activeCount":80},[],{"trials":561,"activeCount":80},[],{"trials":563,"activeCount":80},[],{"trials":565,"activeCount":80},[],{"trials":567,"activeCount":80},[568],{"nctId":543,"briefTitle":544,"status":173,"phases":569,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":570,"interventions":571},[71],[551],[530,553],{"trials":573,"activeCount":80},[],{"intervention":575,"totalTrials":76,"cells":576},"Pitavastatin calcium 4mg",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":598},{"trials":578,"activeCount":80},[],{"trials":580,"activeCount":80},[],{"trials":582,"activeCount":80},[],{"trials":584,"activeCount":80},[],{"trials":586,"activeCount":80},[587],{"nctId":588,"briefTitle":589,"status":173,"phases":590,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT02056847","to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia",[71],"2017-05","2013-09",313,[595],"HbA1c Level Associated With Lipid Compositions",[575,597],"Pitavastatin calcium 2mg",{"trials":599,"activeCount":80},[],{"intervention":597,"totalTrials":76,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":616},{"trials":603,"activeCount":80},[],{"trials":605,"activeCount":80},[],{"trials":607,"activeCount":80},[],{"trials":609,"activeCount":80},[],{"trials":611,"activeCount":80},[612],{"nctId":588,"briefTitle":589,"status":173,"phases":613,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":614,"interventions":615},[71],[595],[575,597],{"trials":617,"activeCount":80},[],{"intervention":619,"totalTrials":76,"cells":620},"venoferrum",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":640},{"trials":622,"activeCount":80},[],{"trials":624,"activeCount":80},[],{"trials":626,"activeCount":80},[],{"trials":628,"activeCount":80},[],{"trials":630,"activeCount":80},[631],{"nctId":632,"briefTitle":633,"status":173,"phases":634,"primaryCompletion":496,"completion":439,"start":548,"enrollment":635,"conditions":636,"interventions":638},"NCT00802139","Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin",[71],58,[637],"Iron Deficiency Anemia",[619,639],"Bolgre",{"trials":641,"activeCount":80},[],{"intervention":639,"totalTrials":76,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":658},{"trials":645,"activeCount":80},[],{"trials":647,"activeCount":80},[],{"trials":649,"activeCount":80},[],{"trials":651,"activeCount":80},[],{"trials":653,"activeCount":80},[654],{"nctId":632,"briefTitle":633,"status":173,"phases":655,"primaryCompletion":496,"completion":439,"start":548,"enrollment":635,"conditions":656,"interventions":657},[71],[637],[619,639],{"trials":659,"activeCount":80},[],{"intervention":661,"totalTrials":76,"cells":662},"recomon",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":684},{"trials":664,"activeCount":80},[],{"trials":666,"activeCount":80},[],{"trials":668,"activeCount":80},[],{"trials":670,"activeCount":80},[],{"trials":672,"activeCount":80},[673],{"nctId":674,"briefTitle":675,"status":173,"phases":676,"primaryCompletion":186,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT01111630","Study of Erythropoietin (EPO) Administration Schedule",[71],"2014-01","2009-10",60,[681,682],"Chronic Renal Failure","Anaemia",[661,661],{"trials":685,"activeCount":80},[],{"intervention":687,"totalTrials":76,"cells":688},"pravastatin",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":697,"NA":709},{"trials":690,"activeCount":80},[],{"trials":692,"activeCount":80},[],{"trials":694,"activeCount":80},[],{"trials":696,"activeCount":80},[],{"trials":698,"activeCount":80},[699],{"nctId":700,"briefTitle":701,"status":173,"phases":702,"primaryCompletion":185,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":708},"NCT00701285","South Korean Pitavastatin Heart Failure Study",[71],"2014-05","2008-07",70,[707],"Chronic Heart Failure",[499,687],{"trials":710,"activeCount":80},[],{"intervention":712,"totalTrials":31,"cells":713},"Epaminurad 9 mg",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":739,"PHASE3":741,"PHASE4":760,"NA":762},{"trials":715,"activeCount":80},[],{"trials":717,"activeCount":80},[718,728],{"nctId":719,"briefTitle":720,"status":173,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT07374406","To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers",[68],"2026-02-19","2026-02-24","2026-02-02",34,[14],[712,712],{"nctId":729,"briefTitle":730,"status":173,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":15,"conditions":735,"interventions":737},"NCT06665425","PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers",[68],"2025-05-02","2025-09-04","2025-03-24",[736],"Healthy Volunteers",[712,738],"C2406",{"trials":740,"activeCount":80},[],{"trials":742,"activeCount":80},[743],{"nctId":744,"briefTitle":745,"status":173,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":752},"NCT05815901","A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients",[70],"2024-03-26","2026-04-23","2023-03-21",612,[28],[753,712,754,755,756,757,758,759],"Epaminurad 6 mg","Febuxostat 40 mg","Febuxostat 80 mg","Epaminurad 6 mg placebo","Epaminurad 9 mg placebo","Febuxostat 40 mg placebo","Febuxostat 80 mg placebo",{"trials":761,"activeCount":80},[],{"trials":763,"activeCount":80},[],{"intervention":765,"totalTrials":34,"cells":766},"LivaloVA",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":783,"PHASE3":785,"PHASE4":797,"NA":799},{"trials":768,"activeCount":80},[],{"trials":770,"activeCount":80},[771],{"nctId":772,"briefTitle":773,"status":173,"phases":774,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":780},"NCT05351840","To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers",[68],"2020-12-19","2021-01-15","2020-11-02",31,[14],[781,782,765],"LivaloV","A",{"trials":784,"activeCount":80},[],{"trials":786,"activeCount":80},[787],{"nctId":788,"briefTitle":789,"status":173,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":795},"NCT05331014","To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension",[70],"2022-11-08","2021-11-15",155,[25,22],[765,781,796],"VA",{"trials":798,"activeCount":80},[],{"trials":800,"activeCount":80},[],{"intervention":781,"totalTrials":34,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":811,"PHASE3":813,"PHASE4":819,"NA":821},{"trials":804,"activeCount":80},[],{"trials":806,"activeCount":80},[807],{"nctId":772,"briefTitle":773,"status":173,"phases":808,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":809,"interventions":810},[68],[14],[781,782,765],{"trials":812,"activeCount":80},[],{"trials":814,"activeCount":80},[815],{"nctId":788,"briefTitle":789,"status":173,"phases":816,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":817,"interventions":818},[70],[25,22],[765,781,796],{"trials":820,"activeCount":80},[],{"trials":822,"activeCount":80},[],{"intervention":824,"totalTrials":34,"cells":825},"Tocilizumab",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":853,"NA":855},{"trials":827,"activeCount":80},[],{"trials":829,"activeCount":80},[],{"trials":831,"activeCount":80},[],{"trials":833,"activeCount":80},[834,845],{"nctId":835,"briefTitle":836,"status":173,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":523,"conditions":841,"interventions":843},"NCT01256736","To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis",[70],"2011-12","2013-11","2010-03",[842],"Rheumatoid Arthritis",[824,844],"DMARDs",{"nctId":846,"briefTitle":847,"status":173,"phases":848,"primaryCompletion":439,"completion":439,"start":678,"enrollment":849,"conditions":850,"interventions":851},"NCT01211834","Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis",[70],90,[842],[852,844,844],"tocilizumab",{"trials":854,"activeCount":80},[],{"trials":856,"activeCount":80},[],{"intervention":844,"totalTrials":34,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":875,"NA":877},{"trials":860,"activeCount":80},[],{"trials":862,"activeCount":80},[],{"trials":864,"activeCount":80},[],{"trials":866,"activeCount":80},[867,871],{"nctId":835,"briefTitle":836,"status":173,"phases":868,"primaryCompletion":838,"completion":839,"start":840,"enrollment":523,"conditions":869,"interventions":870},[70],[842],[824,844],{"nctId":846,"briefTitle":847,"status":173,"phases":872,"primaryCompletion":439,"completion":439,"start":678,"enrollment":849,"conditions":873,"interventions":874},[70],[842],[852,844,844],{"trials":876,"activeCount":80},[],{"trials":878,"activeCount":80},[],{"intervention":880,"totalTrials":76,"cells":881},"Avanafil",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":900,"NA":902},{"trials":883,"activeCount":80},[],{"trials":885,"activeCount":80},[],{"trials":887,"activeCount":80},[],{"trials":889,"activeCount":80},[890],{"nctId":891,"briefTitle":892,"status":173,"phases":893,"primaryCompletion":678,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT00903981","Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil",[70],"2009-11","2009-03",208,[898],"Erectile Dysfunction",[880,880],{"trials":901,"activeCount":80},[],{"trials":903,"activeCount":80},[],{"intervention":905,"totalTrials":76,"cells":906},"JW0108 + C2407",{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":925,"NA":927},{"trials":908,"activeCount":80},[],{"trials":910,"activeCount":80},[],{"trials":912,"activeCount":80},[],{"trials":914,"activeCount":80},[915],{"nctId":916,"briefTitle":917,"status":173,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":923},"NCT06955104","Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia",[70],"2025-07-30","2025-04-03",145,[25],[905,924],"JW0108 + C2407 placebo",{"trials":926,"activeCount":80},[],{"trials":928,"activeCount":80},[],{"intervention":924,"totalTrials":76,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":943,"NA":945},{"trials":932,"activeCount":80},[],{"trials":934,"activeCount":80},[],{"trials":936,"activeCount":80},[],{"trials":938,"activeCount":80},[939],{"nctId":916,"briefTitle":917,"status":173,"phases":940,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":941,"interventions":942},[70],[25],[905,924],{"trials":944,"activeCount":80},[],{"trials":946,"activeCount":80},[],{"intervention":753,"totalTrials":76,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":961,"NA":963},{"trials":950,"activeCount":80},[],{"trials":952,"activeCount":80},[],{"trials":954,"activeCount":80},[],{"trials":956,"activeCount":80},[957],{"nctId":744,"briefTitle":745,"status":173,"phases":958,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":959,"interventions":960},[70],[28],[753,712,754,755,756,757,758,759],{"trials":962,"activeCount":80},[],{"trials":964,"activeCount":80},[],{"intervention":754,"totalTrials":76,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":979,"NA":981},{"trials":968,"activeCount":80},[],{"trials":970,"activeCount":80},[],{"trials":972,"activeCount":80},[],{"trials":974,"activeCount":80},[975],{"nctId":744,"briefTitle":745,"status":173,"phases":976,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":977,"interventions":978},[70],[28],[753,712,754,755,756,757,758,759],{"trials":980,"activeCount":80},[],{"trials":982,"activeCount":80},[],{"intervention":755,"totalTrials":76,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":997,"NA":999},{"trials":986,"activeCount":80},[],{"trials":988,"activeCount":80},[],{"trials":990,"activeCount":80},[],{"trials":992,"activeCount":80},[993],{"nctId":744,"briefTitle":745,"status":173,"phases":994,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":995,"interventions":996},[70],[28],[753,712,754,755,756,757,758,759],{"trials":998,"activeCount":80},[],{"trials":1000,"activeCount":80},[],{"intervention":756,"totalTrials":76,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1009,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":80},[],{"trials":1006,"activeCount":80},[],{"trials":1008,"activeCount":80},[],{"trials":1010,"activeCount":80},[1011],{"nctId":744,"briefTitle":745,"status":173,"phases":1012,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":1013,"interventions":1014},[70],[28],[753,712,754,755,756,757,758,759],{"trials":1016,"activeCount":80},[],{"trials":1018,"activeCount":80},[],{"intervention":757,"totalTrials":76,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":80},[],{"trials":1024,"activeCount":80},[],{"trials":1026,"activeCount":80},[],{"trials":1028,"activeCount":80},[1029],{"nctId":744,"briefTitle":745,"status":173,"phases":1030,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":1031,"interventions":1032},[70],[28],[753,712,754,755,756,757,758,759],{"trials":1034,"activeCount":80},[],{"trials":1036,"activeCount":80},[],{"intervention":758,"totalTrials":76,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":80},[],{"trials":1042,"activeCount":80},[],{"trials":1044,"activeCount":80},[],{"trials":1046,"activeCount":80},[1047],{"nctId":744,"briefTitle":745,"status":173,"phases":1048,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":1049,"interventions":1050},[70],[28],[753,712,754,755,756,757,758,759],{"trials":1052,"activeCount":80},[],{"trials":1054,"activeCount":80},[],{"intervention":759,"totalTrials":76,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":80},[],{"trials":1060,"activeCount":80},[],{"trials":1062,"activeCount":80},[],{"trials":1064,"activeCount":80},[1065],{"nctId":744,"briefTitle":745,"status":173,"phases":1066,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":1067,"interventions":1068},[70],[28],[753,712,754,755,756,757,758,759],{"trials":1070,"activeCount":80},[],{"trials":1072,"activeCount":80},[],{"intervention":796,"totalTrials":76,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":80},[],{"trials":1078,"activeCount":80},[],{"trials":1080,"activeCount":80},[],{"trials":1082,"activeCount":80},[1083],{"nctId":788,"briefTitle":789,"status":173,"phases":1084,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":1085,"interventions":1086},[70],[25,22],[765,781,796],{"trials":1088,"activeCount":80},[],{"trials":1090,"activeCount":80},[],{"intervention":1092,"totalTrials":76,"cells":1093},"pitavastatin, valsartan, placebo",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1112,"NA":1114},{"trials":1095,"activeCount":80},[],{"trials":1097,"activeCount":80},[],{"trials":1099,"activeCount":80},[],{"trials":1101,"activeCount":80},[1102],{"nctId":1103,"briefTitle":1104,"status":173,"phases":1105,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1111},"NCT01402843","Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia",[70],"2012-06","2013-01","2011-06",150,[22,25],[1092],{"trials":1113,"activeCount":80},[],{"trials":1115,"activeCount":80},[],{"intervention":1117,"totalTrials":76,"cells":1118},"JW0201",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1136,"NA":1138},{"trials":1120,"activeCount":80},[],{"trials":1122,"activeCount":80},[],{"trials":1124,"activeCount":80},[],{"trials":1126,"activeCount":80},[1127],{"nctId":1128,"briefTitle":1129,"status":173,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT05814406","To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM",[70],"2024-03-21","2023-01-12",196,[19],[1117],{"trials":1137,"activeCount":80},[],{"trials":1139,"activeCount":80},[],{"intervention":1141,"totalTrials":76,"cells":1142},"JTZ-951",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1162,"NA":1164},{"trials":1144,"activeCount":80},[],{"trials":1146,"activeCount":80},[],{"trials":1148,"activeCount":80},[],{"trials":1150,"activeCount":80},[1151],{"nctId":1152,"briefTitle":1153,"status":173,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT04027517","A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.",[70],"2021-02-23","2019-01-15",172,[1159],"Anemia of Chronic Kidney Disease",[1141,1161],"Darbepoetin Alfa",{"trials":1163,"activeCount":80},[],{"trials":1165,"activeCount":80},[],{"intervention":1161,"totalTrials":76,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":80},[],{"trials":1171,"activeCount":80},[],{"trials":1173,"activeCount":80},[],{"trials":1175,"activeCount":80},[1176],{"nctId":1152,"briefTitle":1153,"status":173,"phases":1177,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1178,"interventions":1179},[70],[1159],[1141,1161],{"trials":1181,"activeCount":80},[],{"trials":1183,"activeCount":80},[],{"intervention":1185,"totalTrials":76,"cells":1186},"Livalo, Ezetrol",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1206,"NA":1208},{"trials":1188,"activeCount":80},[],{"trials":1190,"activeCount":80},[],{"trials":1192,"activeCount":80},[],{"trials":1194,"activeCount":80},[1195],{"nctId":1196,"briefTitle":1197,"status":173,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT04584736","To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia",[70],"2020-07-16","2020-10-12","2019-06-11",283,[1204],"Primary Hypercholesterolemia",[1185],{"trials":1207,"activeCount":80},[],{"trials":1209,"activeCount":80},[],{"intervention":190,"totalTrials":76,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1224,"NA":1226},{"trials":1213,"activeCount":80},[],{"trials":1215,"activeCount":80},[],{"trials":1217,"activeCount":80},[],{"trials":1219,"activeCount":80},[1220],{"nctId":182,"briefTitle":183,"status":173,"phases":1221,"primaryCompletion":185,"completion":186,"start":177,"enrollment":187,"conditions":1222,"interventions":1223},[70],[19],[119,190],{"trials":1225,"activeCount":80},[],{"trials":1227,"activeCount":80},[],{"intervention":1229,"totalTrials":76,"cells":1230},"Treatment Period",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1249,"NA":1251},{"trials":1232,"activeCount":80},[],{"trials":1234,"activeCount":80},[],{"trials":1236,"activeCount":80},[],{"trials":1238,"activeCount":80},[1239],{"nctId":1240,"briefTitle":1241,"status":173,"phases":1242,"primaryCompletion":1243,"completion":1244,"start":1245,"enrollment":187,"conditions":1246,"interventions":1247},"NCT05814393","To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus",[70],"2024-05-14","2024-11-20","2023-01-03",[19],[1229,1229,1248],"Extension Period",{"trials":1250,"activeCount":80},[],{"trials":1252,"activeCount":80},[],{"intervention":1248,"totalTrials":76,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":80},[],{"trials":1258,"activeCount":80},[],{"trials":1260,"activeCount":80},[],{"trials":1262,"activeCount":80},[1263],{"nctId":1240,"briefTitle":1241,"status":173,"phases":1264,"primaryCompletion":1243,"completion":1244,"start":1245,"enrollment":187,"conditions":1265,"interventions":1266},[70],[19],[1229,1229,1248],{"trials":1268,"activeCount":80},[],{"trials":1270,"activeCount":80},[],{"intervention":1272,"totalTrials":76,"cells":1273},"Avanafil 100 or 200mg",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1280,"PHASE4":1291,"NA":1293},{"trials":1275,"activeCount":80},[],{"trials":1277,"activeCount":80},[],{"trials":1279,"activeCount":80},[],{"trials":1281,"activeCount":80},[1282],{"nctId":1283,"briefTitle":1284,"status":173,"phases":1285,"primaryCompletion":1286,"completion":839,"start":1287,"enrollment":1288,"conditions":1289,"interventions":1290},"NCT01705197","This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.",[70],"2013-04","2012-02",195,[898],[1272],{"trials":1292,"activeCount":80},[],{"trials":1294,"activeCount":80},[],{"intervention":1296,"totalTrials":26,"cells":1297},"URC102",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1332,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1299,"activeCount":80},[],{"trials":1301,"activeCount":80},[1302,1312,1322],{"nctId":1303,"briefTitle":1304,"status":173,"phases":1305,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT02524678","Phase 1 Study(Additional) of URC102 in Healthy Subjects",[68],"2015-10-07","2016-03-28","2015-08-05",21,[14],[1296],{"nctId":1313,"briefTitle":1314,"status":173,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1321},"NCT05198778","A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment",[68],"2022-07-13","2021-11-29",28,[1320],"Healthy, Renal Impairment",[1296,1296],{"nctId":1323,"briefTitle":1324,"status":173,"phases":1325,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT01953497","Phase 1 Study of URC102 in Healthy Subjects",[68],"2013-12-24","2014-07","2013-05-23",81,[14],[1296],{"trials":1333,"activeCount":80},[1334],{"nctId":1335,"briefTitle":1336,"status":173,"phases":1337,"primaryCompletion":1338,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1343},"NCT02557126","Study of URC102 to Assess the Safety and Efficacy in Gout Patients",[69],"2016-08","2015-10",76,[28,1342],"Hyperuricemia",[1296],{"trials":1345,"activeCount":80},[],{"trials":1347,"activeCount":80},[],{"trials":1349,"activeCount":80},[],{"intervention":1351,"totalTrials":26,"cells":1352},"LEO 152020",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1376,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1354,"activeCount":80},[],{"trials":1356,"activeCount":80},[1357,1367],{"nctId":1358,"briefTitle":1359,"status":173,"phases":1360,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":1318,"conditions":1363,"interventions":1365},"NCT05508776","A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People",[68],"2022-12-28","2022-09-16",[736,1364],"Cardiac Repolarisation",[1351,1366],"Moxifloxacin",{"nctId":1368,"briefTitle":1369,"status":173,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1375},"NCT04203836","A Trial to Evaluate the Effect of Food on LEO 152020",[68],"2020-12-12","2020-01-09",12,[14],[1351],{"trials":1377,"activeCount":80},[1378,1390],{"nctId":1379,"briefTitle":1380,"status":173,"phases":1381,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1388},"NCT04853992","Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria",[69],"2022-07-08","2022-07-11","2021-05-10",20,[1387],"Cholinergic Urticaria",[1351,1389],"LEO 152020 placebo",{"nctId":1391,"briefTitle":1392,"status":173,"phases":1393,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT05117060","Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis",[69],"2023-07-20","2023-07-26","2021-12-13",216,[1399],"Atopic Dermatitis",[1351,1389],{"trials":1402,"activeCount":80},[],{"trials":1404,"activeCount":80},[],{"trials":1406,"activeCount":80},[],{"intervention":1389,"totalTrials":34,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1410,"activeCount":80},[],{"trials":1412,"activeCount":80},[],{"trials":1414,"activeCount":80},[1415,1419],{"nctId":1379,"briefTitle":1380,"status":173,"phases":1416,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1417,"interventions":1418},[69],[1387],[1351,1389],{"nctId":1391,"briefTitle":1392,"status":173,"phases":1420,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":1397,"conditions":1421,"interventions":1422},[69],[1399],[1351,1389],{"trials":1424,"activeCount":80},[],{"trials":1426,"activeCount":80},[],{"trials":1428,"activeCount":80},[],{"intervention":1430,"totalTrials":34,"cells":1431},"CWP232291",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1449,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1433,"activeCount":80},[],{"trials":1435,"activeCount":80},[1436],{"nctId":1437,"briefTitle":1438,"status":173,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1448},"NCT01398462","Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients",[68],"2015-12","2011-07",69,[1444,1445,1446,1447],"Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome","Myelofibrosis",[1430],{"trials":1450,"activeCount":80},[1451],{"nctId":1452,"briefTitle":1453,"status":1454,"phases":1455,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1460},"NCT03055286","Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients","TERMINATED",[68,69],"2025-08-26","2017-02-06",15,[1444],[1430],{"trials":1462,"activeCount":80},[],{"trials":1464,"activeCount":80},[],{"trials":1466,"activeCount":80},[],{"intervention":1468,"totalTrials":76,"cells":1469},"arm 0",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1471,"activeCount":80},[],{"trials":1473,"activeCount":80},[],{"trials":1475,"activeCount":80},[1476],{"nctId":1477,"briefTitle":1478,"status":173,"phases":1479,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1485},"NCT04804111","Study of of URC102 to Assess the Efficacy and Safety in Gout Patients",[69],"2020-09-04","2020-11-29","2019-01-21",171,[28],[1468,1486,1487,1488,1489],"arm 1","arm 2","arm 3","arm 4",{"trials":1491,"activeCount":80},[],{"trials":1493,"activeCount":80},[],{"trials":1495,"activeCount":80},[],{"intervention":1486,"totalTrials":76,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":80},[],{"trials":1501,"activeCount":80},[],{"trials":1503,"activeCount":80},[1504],{"nctId":1477,"briefTitle":1478,"status":173,"phases":1505,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1506,"interventions":1507},[69],[28],[1468,1486,1487,1488,1489],{"trials":1509,"activeCount":80},[],{"trials":1511,"activeCount":80},[],{"trials":1513,"activeCount":80},[],{"intervention":1487,"totalTrials":76,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":80},[],{"trials":1519,"activeCount":80},[],{"trials":1521,"activeCount":80},[1522],{"nctId":1477,"briefTitle":1478,"status":173,"phases":1523,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1524,"interventions":1525},[69],[28],[1468,1486,1487,1488,1489],{"trials":1527,"activeCount":80},[],{"trials":1529,"activeCount":80},[],{"trials":1531,"activeCount":80},[],{"intervention":1488,"totalTrials":76,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":80},[],{"trials":1537,"activeCount":80},[],{"trials":1539,"activeCount":80},[1540],{"nctId":1477,"briefTitle":1478,"status":173,"phases":1541,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1542,"interventions":1543},[69],[28],[1468,1486,1487,1488,1489],{"trials":1545,"activeCount":80},[],{"trials":1547,"activeCount":80},[],{"trials":1549,"activeCount":80},[],{"intervention":1489,"totalTrials":76,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":80},[],{"trials":1555,"activeCount":80},[],{"trials":1557,"activeCount":80},[1558],{"nctId":1477,"briefTitle":1478,"status":173,"phases":1559,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1560,"interventions":1561},[69],[28],[1468,1486,1487,1488,1489],{"trials":1563,"activeCount":80},[],{"trials":1565,"activeCount":80},[],{"trials":1567,"activeCount":80},[],{"intervention":1569,"totalTrials":76,"cells":1570},"URC102 0.25mg",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1572,"activeCount":80},[],{"trials":1574,"activeCount":80},[],{"trials":1576,"activeCount":80},[1577],{"nctId":1578,"briefTitle":1579,"status":173,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1586},"NCT02290210","Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients",[69],"2014-12-02","2015-08-31","2014-07-24",64,[28,1342],[1569,1587,1588,1589],"URC102 0.5mg","URC102 1.0mg","URC102 2.0mg",{"trials":1591,"activeCount":80},[],{"trials":1593,"activeCount":80},[],{"trials":1595,"activeCount":80},[],{"intervention":1587,"totalTrials":76,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":80},[],{"trials":1601,"activeCount":80},[],{"trials":1603,"activeCount":80},[1604],{"nctId":1578,"briefTitle":1579,"status":173,"phases":1605,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1606,"interventions":1607},[69],[28,1342],[1569,1587,1588,1589],{"trials":1609,"activeCount":80},[],{"trials":1611,"activeCount":80},[],{"trials":1613,"activeCount":80},[],{"intervention":1588,"totalTrials":76,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1617,"activeCount":80},[],{"trials":1619,"activeCount":80},[],{"trials":1621,"activeCount":80},[1622],{"nctId":1578,"briefTitle":1579,"status":173,"phases":1623,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1624,"interventions":1625},[69],[28,1342],[1569,1587,1588,1589],{"trials":1627,"activeCount":80},[],{"trials":1629,"activeCount":80},[],{"trials":1631,"activeCount":80},[],{"intervention":1589,"totalTrials":76,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":80},[],{"trials":1637,"activeCount":80},[],{"trials":1639,"activeCount":80},[1640],{"nctId":1578,"briefTitle":1579,"status":173,"phases":1641,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1642,"interventions":1643},[69],[28,1342],[1569,1587,1588,1589],{"trials":1645,"activeCount":80},[],{"trials":1647,"activeCount":80},[],{"trials":1649,"activeCount":80},[],{"intervention":1651,"totalTrials":76,"cells":1652},"CWP-0403 100mg",{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1654,"activeCount":80},[],{"trials":1656,"activeCount":80},[],{"trials":1658,"activeCount":80},[1659],{"nctId":1660,"briefTitle":1661,"status":173,"phases":1662,"primaryCompletion":484,"completion":1663,"start":1664,"enrollment":921,"conditions":1665,"interventions":1666},"NCT00888719","Therapeutic Exploratory Study of CWP-0403",[69],"2010-04","2009-02",[19],[1651,1667],"CWP-0403 50mg",{"trials":1669,"activeCount":80},[],{"trials":1671,"activeCount":80},[],{"trials":1673,"activeCount":80},[],{"intervention":1667,"totalTrials":76,"cells":1675},{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1677,"activeCount":80},[],{"trials":1679,"activeCount":80},[],{"trials":1681,"activeCount":80},[1682],{"nctId":1660,"briefTitle":1661,"status":173,"phases":1683,"primaryCompletion":484,"completion":1663,"start":1664,"enrollment":921,"conditions":1684,"interventions":1685},[69],[19],[1651,1667],{"trials":1687,"activeCount":80},[],{"trials":1689,"activeCount":80},[],{"trials":1691,"activeCount":80},[],{"intervention":1693,"totalTrials":31,"cells":1694},"Reference Drug or Test Drug",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1696,"activeCount":80},[],{"trials":1698,"activeCount":80},[1699,1709,1719],{"nctId":1700,"briefTitle":1701,"status":173,"phases":1702,"primaryCompletion":1703,"completion":1704,"start":1705,"enrollment":1706,"conditions":1707,"interventions":1708},"NCT06355349","To Evaluate the Safety and PK Characteristics in Healthy Volunteers",[68],"2023-07-10","2023-07-17","2023-04-28",46,[14],[1693],{"nctId":1710,"briefTitle":1711,"status":173,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1718},"NCT05433844","To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers",[68],"2022-08-26","2022-09-14","2022-06-02",44,[14],[1693],{"nctId":1720,"briefTitle":1721,"status":173,"phases":1722,"primaryCompletion":1723,"completion":1724,"start":1725,"enrollment":1726,"conditions":1727,"interventions":1728},"NCT06361277","To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers",[68],"2023-11-20","2023-11-27","2023-11-03",56,[14],[1693],{"trials":1730,"activeCount":80},[],{"trials":1732,"activeCount":80},[],{"trials":1734,"activeCount":80},[],{"trials":1736,"activeCount":80},[],{"intervention":1738,"totalTrials":34,"cells":1739},"Pitavastatin, Valsartan",{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1741,"activeCount":80},[],{"trials":1743,"activeCount":80},[1744,1755],{"nctId":1745,"briefTitle":1746,"status":173,"phases":1747,"primaryCompletion":1748,"completion":1749,"start":1748,"enrollment":1750,"conditions":1751,"interventions":1753},"NCT01406431","Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects",[68],"2011-08","2012-10",48,[1752,22],"Hyperlipidemia",[1738,1754],"Livalo® fixed combination drug",{"nctId":1756,"briefTitle":1757,"status":173,"phases":1758,"primaryCompletion":1759,"completion":1760,"start":1761,"enrollment":1762,"conditions":1763,"interventions":1764},"NCT01764178","To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet",[68],"2013-03-15","2013-12-27","2013-01-22",52,[1752,22],[1765,1738],"Livalo fixed combination drug",{"trials":1767,"activeCount":80},[],{"trials":1769,"activeCount":80},[],{"trials":1771,"activeCount":80},[],{"trials":1773,"activeCount":80},[],{"intervention":1754,"totalTrials":76,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":80},[],{"trials":1779,"activeCount":80},[1780],{"nctId":1745,"briefTitle":1746,"status":173,"phases":1781,"primaryCompletion":1748,"completion":1749,"start":1748,"enrollment":1750,"conditions":1782,"interventions":1783},[68],[1752,22],[1738,1754],{"trials":1785,"activeCount":80},[],{"trials":1787,"activeCount":80},[],{"trials":1789,"activeCount":80},[],{"trials":1791,"activeCount":80},[],{"intervention":1793,"totalTrials":76,"cells":1794},"Treatment A",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1796,"activeCount":80},[],{"trials":1798,"activeCount":80},[1799],{"nctId":1800,"briefTitle":1801,"status":173,"phases":1802,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1808},"NCT05463497","To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers",[68],"2022-03-16","2022-03-23","2022-01-17",40,[14],[1793,1809,1810,1811,1812],"Treatment B","Treatment C","Treatment D","Treatment E",{"trials":1814,"activeCount":80},[],{"trials":1816,"activeCount":80},[],{"trials":1818,"activeCount":80},[],{"trials":1820,"activeCount":80},[],{"intervention":1809,"totalTrials":76,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1824,"activeCount":80},[],{"trials":1826,"activeCount":80},[1827],{"nctId":1800,"briefTitle":1801,"status":173,"phases":1828,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1829,"interventions":1830},[68],[14],[1793,1809,1810,1811,1812],{"trials":1832,"activeCount":80},[],{"trials":1834,"activeCount":80},[],{"trials":1836,"activeCount":80},[],{"trials":1838,"activeCount":80},[],{"intervention":1810,"totalTrials":76,"cells":1840},{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1855},{"trials":1842,"activeCount":80},[],{"trials":1844,"activeCount":80},[1845],{"nctId":1800,"briefTitle":1801,"status":173,"phases":1846,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1847,"interventions":1848},[68],[14],[1793,1809,1810,1811,1812],{"trials":1850,"activeCount":80},[],{"trials":1852,"activeCount":80},[],{"trials":1854,"activeCount":80},[],{"trials":1856,"activeCount":80},[],{"intervention":1811,"totalTrials":76,"cells":1858},{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1867,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1860,"activeCount":80},[],{"trials":1862,"activeCount":80},[1863],{"nctId":1800,"briefTitle":1801,"status":173,"phases":1864,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1865,"interventions":1866},[68],[14],[1793,1809,1810,1811,1812],{"trials":1868,"activeCount":80},[],{"trials":1870,"activeCount":80},[],{"trials":1872,"activeCount":80},[],{"trials":1874,"activeCount":80},[],{"intervention":1812,"totalTrials":76,"cells":1876},{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1878,"activeCount":80},[],{"trials":1880,"activeCount":80},[1881],{"nctId":1800,"briefTitle":1801,"status":173,"phases":1882,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1883,"interventions":1884},[68],[14],[1793,1809,1810,1811,1812],{"trials":1886,"activeCount":80},[],{"trials":1888,"activeCount":80},[],{"trials":1890,"activeCount":80},[],{"trials":1892,"activeCount":80},[],{"intervention":1894,"totalTrials":76,"cells":1895},"14C Epaminurad Oral Solution",{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1897,"activeCount":80},[],{"trials":1899,"activeCount":80},[1900],{"nctId":1901,"briefTitle":1902,"status":173,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1909},"NCT07036458","To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects",[68],"2025-09-05","2025-08-22",8,[1908],"Healthy Male Adults",[1894],{"trials":1911,"activeCount":80},[],{"trials":1913,"activeCount":80},[],{"trials":1915,"activeCount":80},[],{"trials":1917,"activeCount":80},[],{"intervention":1919,"totalTrials":76,"cells":1920},"Phase 1a: CWP232291",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1937,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1922,"activeCount":80},[],{"trials":1924,"activeCount":80},[1925],{"nctId":1926,"briefTitle":1927,"status":173,"phases":1928,"primaryCompletion":1929,"completion":1930,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1935},"NCT02426723","Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients",[68],"2018-10-08","2018-10-26","2015-10-19",25,[1934],"Multiple Myeloma",[1919,1936],"Phase 1b: CWP232291, Lenalidomide, Dexamethasone",{"trials":1938,"activeCount":80},[],{"trials":1940,"activeCount":80},[],{"trials":1942,"activeCount":80},[],{"trials":1944,"activeCount":80},[],{"intervention":1936,"totalTrials":76,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":80},[],{"trials":1950,"activeCount":80},[1951],{"nctId":1926,"briefTitle":1927,"status":173,"phases":1952,"primaryCompletion":1929,"completion":1930,"start":1931,"enrollment":1932,"conditions":1953,"interventions":1954},[68],[1934],[1919,1936],{"trials":1956,"activeCount":80},[],{"trials":1958,"activeCount":80},[],{"trials":1960,"activeCount":80},[],{"trials":1962,"activeCount":80},[],{"intervention":1366,"totalTrials":76,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1973,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1966,"activeCount":80},[],{"trials":1968,"activeCount":80},[1969],{"nctId":1358,"briefTitle":1359,"status":173,"phases":1970,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":1318,"conditions":1971,"interventions":1972},[68],[736,1364],[1351,1366],{"trials":1974,"activeCount":80},[],{"trials":1976,"activeCount":80},[],{"trials":1978,"activeCount":80},[],{"trials":1980,"activeCount":80},[],{"intervention":1982,"totalTrials":76,"cells":1983},"Study drug",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1997,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1985,"activeCount":80},[],{"trials":1987,"activeCount":80},[1988],{"nctId":1989,"briefTitle":1990,"status":173,"phases":1991,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":1994,"conditions":1995,"interventions":1996},"NCT04018170","Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers",[68],"2019-12-15","2019-02-15",102,[14],[1982],{"trials":1998,"activeCount":80},[],{"trials":2000,"activeCount":80},[],{"trials":2002,"activeCount":80},[],{"trials":2004,"activeCount":80},[],{"intervention":2006,"totalTrials":76,"cells":2007},"Group 1: JW0104",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2026,"PHASE3":2028,"PHASE4":2030,"NA":2032},{"trials":2009,"activeCount":80},[],{"trials":2011,"activeCount":80},[2012],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2019,"interventions":2020},"NCT06378684","To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers",[68],"2023-12-23","2024-01-13","2023-09-10",[14],[2006,2021,2022,2023,2024,2025],"Group 2: JW0104 + C2207","Group 3: C2207","Group 4: JW0104","Group 5: JW0104 + C2207","Group 6: C2207",{"trials":2027,"activeCount":80},[],{"trials":2029,"activeCount":80},[],{"trials":2031,"activeCount":80},[],{"trials":2033,"activeCount":80},[],{"intervention":2021,"totalTrials":76,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2050},{"trials":2037,"activeCount":80},[],{"trials":2039,"activeCount":80},[2040],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2041,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2042,"interventions":2043},[68],[14],[2006,2021,2022,2023,2024,2025],{"trials":2045,"activeCount":80},[],{"trials":2047,"activeCount":80},[],{"trials":2049,"activeCount":80},[],{"trials":2051,"activeCount":80},[],{"intervention":2022,"totalTrials":76,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2055,"activeCount":80},[],{"trials":2057,"activeCount":80},[2058],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2059,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2060,"interventions":2061},[68],[14],[2006,2021,2022,2023,2024,2025],{"trials":2063,"activeCount":80},[],{"trials":2065,"activeCount":80},[],{"trials":2067,"activeCount":80},[],{"trials":2069,"activeCount":80},[],{"intervention":2023,"totalTrials":76,"cells":2071},{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2080,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2073,"activeCount":80},[],{"trials":2075,"activeCount":80},[2076],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2077,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2078,"interventions":2079},[68],[14],[2006,2021,2022,2023,2024,2025],{"trials":2081,"activeCount":80},[],{"trials":2083,"activeCount":80},[],{"trials":2085,"activeCount":80},[],{"trials":2087,"activeCount":80},[],{"intervention":2024,"totalTrials":76,"cells":2089},{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2091,"activeCount":80},[],{"trials":2093,"activeCount":80},[2094],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2095,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2096,"interventions":2097},[68],[14],[2006,2021,2022,2023,2024,2025],{"trials":2099,"activeCount":80},[],{"trials":2101,"activeCount":80},[],{"trials":2103,"activeCount":80},[],{"trials":2105,"activeCount":80},[],{"intervention":2025,"totalTrials":76,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2109,"activeCount":80},[],{"trials":2111,"activeCount":80},[2112],{"nctId":2013,"briefTitle":2014,"status":173,"phases":2113,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":1750,"conditions":2114,"interventions":2115},[68],[14],[2006,2021,2022,2023,2024,2025],{"trials":2117,"activeCount":80},[],{"trials":2119,"activeCount":80},[],{"trials":2121,"activeCount":80},[],{"trials":2123,"activeCount":80},[],{"intervention":2125,"totalTrials":76,"cells":2126},"mitiglinide and metformin",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2128,"activeCount":80},[],{"trials":2130,"activeCount":80},[2131],{"nctId":2132,"briefTitle":2133,"status":173,"phases":2134,"primaryCompletion":2135,"completion":2135,"start":460,"enrollment":2136,"conditions":2137,"interventions":2138},"NCT01443221","Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.",[68],"2011-01",24,[14],[2125,2125],{"trials":2140,"activeCount":80},[],{"trials":2142,"activeCount":80},[],{"trials":2144,"activeCount":80},[],{"trials":2146,"activeCount":80},[],{"intervention":1765,"totalTrials":76,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":80},[],{"trials":2152,"activeCount":80},[2153],{"nctId":1756,"briefTitle":1757,"status":173,"phases":2154,"primaryCompletion":1759,"completion":1760,"start":1761,"enrollment":1762,"conditions":2155,"interventions":2156},[68],[1752,22],[1765,1738],{"trials":2158,"activeCount":80},[],{"trials":2160,"activeCount":80},[],{"trials":2162,"activeCount":80},[],{"trials":2164,"activeCount":80},[],{"intervention":2166,"totalTrials":76,"cells":2167},"Treatment A: JW0106 1 tablet + C2101 1",{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2169,"activeCount":80},[],{"trials":2171,"activeCount":80},[2172],{"nctId":2173,"briefTitle":2174,"status":173,"phases":2175,"primaryCompletion":2176,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2181},"NCT06816719","To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107",[68],"2024-11-02","2024-11-12","2024-09-02",47,[14],[2166,2182],"Treatment B: JW0107 1",{"trials":2184,"activeCount":80},[],{"trials":2186,"activeCount":80},[],{"trials":2188,"activeCount":80},[],{"trials":2190,"activeCount":80},[],{"intervention":2182,"totalTrials":76,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2201,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":80},[],{"trials":2196,"activeCount":80},[2197],{"nctId":2173,"briefTitle":2174,"status":173,"phases":2198,"primaryCompletion":2176,"completion":2177,"start":2178,"enrollment":2179,"conditions":2199,"interventions":2200},[68],[14],[2166,2182],{"trials":2202,"activeCount":80},[],{"trials":2204,"activeCount":80},[],{"trials":2206,"activeCount":80},[],{"trials":2208,"activeCount":80},[],{"intervention":782,"totalTrials":76,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":80},[],{"trials":2214,"activeCount":80},[2215],{"nctId":772,"briefTitle":773,"status":173,"phases":2216,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":2217,"interventions":2218},[68],[14],[781,782,765],{"trials":2220,"activeCount":80},[],{"trials":2222,"activeCount":80},[],{"trials":2224,"activeCount":80},[],{"trials":2226,"activeCount":80},[],{"intervention":2228,"totalTrials":76,"cells":2229},"Treatment A_Period 1",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2231,"activeCount":80},[],{"trials":2233,"activeCount":80},[2234],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2237,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2240,"interventions":2241},"NCT06754943","To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105",[68],"2025-04-22","2025-01-17",[14],[2228,2242,2243,2244,2245,2246,2247,2248],"Treatment B_Period 2","Treatment A_Period 3","Treatment B_Period 4","Treatment B_Period 1","Treatment A_Period 2","Treatment B_Period 3","Treatment A_Period 4",{"trials":2250,"activeCount":80},[],{"trials":2252,"activeCount":80},[],{"trials":2254,"activeCount":80},[],{"trials":2256,"activeCount":80},[],{"intervention":2242,"totalTrials":76,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":80},[],{"trials":2262,"activeCount":80},[2263],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2264,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2265,"interventions":2266},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2268,"activeCount":80},[],{"trials":2270,"activeCount":80},[],{"trials":2272,"activeCount":80},[],{"trials":2274,"activeCount":80},[],{"intervention":2243,"totalTrials":76,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2278,"activeCount":80},[],{"trials":2280,"activeCount":80},[2281],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2282,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2283,"interventions":2284},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2286,"activeCount":80},[],{"trials":2288,"activeCount":80},[],{"trials":2290,"activeCount":80},[],{"trials":2292,"activeCount":80},[],{"intervention":2244,"totalTrials":76,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2296,"activeCount":80},[],{"trials":2298,"activeCount":80},[2299],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2300,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2301,"interventions":2302},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2304,"activeCount":80},[],{"trials":2306,"activeCount":80},[],{"trials":2308,"activeCount":80},[],{"trials":2310,"activeCount":80},[],{"intervention":2245,"totalTrials":76,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2314,"activeCount":80},[],{"trials":2316,"activeCount":80},[2317],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2318,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2319,"interventions":2320},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2322,"activeCount":80},[],{"trials":2324,"activeCount":80},[],{"trials":2326,"activeCount":80},[],{"trials":2328,"activeCount":80},[],{"intervention":2246,"totalTrials":76,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2332,"activeCount":80},[],{"trials":2334,"activeCount":80},[2335],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2336,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2337,"interventions":2338},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2340,"activeCount":80},[],{"trials":2342,"activeCount":80},[],{"trials":2344,"activeCount":80},[],{"trials":2346,"activeCount":80},[],{"intervention":2247,"totalTrials":76,"cells":2348},{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2350,"activeCount":80},[],{"trials":2352,"activeCount":80},[2353],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2354,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2355,"interventions":2356},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2358,"activeCount":80},[],{"trials":2360,"activeCount":80},[],{"trials":2362,"activeCount":80},[],{"trials":2364,"activeCount":80},[],{"intervention":2248,"totalTrials":76,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2368,"activeCount":80},[],{"trials":2370,"activeCount":80},[2371],{"nctId":2235,"briefTitle":2236,"status":173,"phases":2372,"primaryCompletion":734,"completion":2238,"start":2239,"enrollment":679,"conditions":2373,"interventions":2374},[68],[14],[2228,2242,2243,2244,2245,2246,2247,2248],{"trials":2376,"activeCount":80},[],{"trials":2378,"activeCount":80},[],{"trials":2380,"activeCount":80},[],{"trials":2382,"activeCount":80},[],{"intervention":2384,"totalTrials":76,"cells":2385},"Epaminurad, Naproxen",{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2387,"activeCount":80},[],{"trials":2389,"activeCount":80},[2390],{"nctId":2391,"briefTitle":2392,"status":173,"phases":2393,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":2396,"conditions":2397,"interventions":2398},"NCT06435442","PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers",[68],"2025-12-30","2024-06-03",57,[14],[2384,2399,2400],"Epaminurad","Epaminurad placebo",{"trials":2402,"activeCount":80},[],{"trials":2404,"activeCount":80},[],{"trials":2406,"activeCount":80},[],{"trials":2408,"activeCount":80},[],{"intervention":2399,"totalTrials":76,"cells":2410},{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2412,"activeCount":80},[],{"trials":2414,"activeCount":80},[2415],{"nctId":2391,"briefTitle":2392,"status":173,"phases":2416,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":2396,"conditions":2417,"interventions":2418},[68],[14],[2384,2399,2400],{"trials":2420,"activeCount":80},[],{"trials":2422,"activeCount":80},[],{"trials":2424,"activeCount":80},[],{"trials":2426,"activeCount":80},[],{"intervention":2400,"totalTrials":76,"cells":2428},{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2443},{"trials":2430,"activeCount":80},[],{"trials":2432,"activeCount":80},[2433],{"nctId":2391,"briefTitle":2392,"status":173,"phases":2434,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":2396,"conditions":2435,"interventions":2436},[68],[14],[2384,2399,2400],{"trials":2438,"activeCount":80},[],{"trials":2440,"activeCount":80},[],{"trials":2442,"activeCount":80},[],{"trials":2444,"activeCount":80},[],{"intervention":2446,"totalTrials":76,"cells":2447},"Test Drug",{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2449,"activeCount":80},[],{"trials":2451,"activeCount":80},[2452],{"nctId":2453,"briefTitle":2454,"status":173,"phases":2455,"primaryCompletion":2456,"completion":2457,"start":2458,"enrollment":1716,"conditions":2459,"interventions":2460},"NCT05784155","To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers",[68],"2023-06-09","2023-06-26","2023-03-10",[14],[2446],{"trials":2462,"activeCount":80},[],{"trials":2464,"activeCount":80},[],{"trials":2466,"activeCount":80},[],{"trials":2468,"activeCount":80},[],{"intervention":738,"totalTrials":76,"cells":2470},{"EARLY_PHASE1":2471,"PHASE1":2473,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2472,"activeCount":80},[],{"trials":2474,"activeCount":80},[2475],{"nctId":729,"briefTitle":730,"status":173,"phases":2476,"primaryCompletion":732,"completion":733,"start":734,"enrollment":15,"conditions":2477,"interventions":2478},[68],[736],[712,738],{"trials":2480,"activeCount":80},[],{"trials":2482,"activeCount":80},[],{"trials":2484,"activeCount":80},[],{"trials":2486,"activeCount":80},[],{"intervention":490,"totalTrials":20,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2529},{"trials":2490,"activeCount":80},[],{"trials":2492,"activeCount":80},[],{"trials":2494,"activeCount":80},[],{"trials":2496,"activeCount":80},[],{"trials":2498,"activeCount":80},[2499,2503,2507,2511,2521],{"nctId":480,"briefTitle":481,"status":173,"phases":2500,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":2501,"interventions":2502},[71],[488],[490,467],{"nctId":492,"briefTitle":493,"status":173,"phases":2504,"primaryCompletion":438,"completion":495,"start":496,"enrollment":187,"conditions":2505,"interventions":2506},[71],[17],[499,500],{"nctId":700,"briefTitle":701,"status":173,"phases":2508,"primaryCompletion":185,"completion":703,"start":704,"enrollment":705,"conditions":2509,"interventions":2510},[71],[707],[499,687],{"nctId":2512,"briefTitle":2513,"status":2514,"phases":2515,"primaryCompletion":483,"completion":2516,"start":2517,"enrollment":80,"conditions":2518,"interventions":2520},"NCT00786734","Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)","WITHDRAWN",[71],"2010-07","2008-08",[2519],"Percutaneous Coronary Intervention",[490,490],{"nctId":2522,"briefTitle":2523,"status":173,"phases":2524,"primaryCompletion":495,"completion":1108,"start":485,"enrollment":2525,"conditions":2526,"interventions":2528},"NCT00640276","Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome",[71],187,[17,2527],"Metabolic Syndrome",[499],{"trials":2530,"activeCount":80},[2531],{"nctId":2532,"briefTitle":2533,"status":173,"phases":2534,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":2539,"interventions":2540},"NCT04402112","Efficacy and Safety of Pitavastatin in a Real-world Setting",[],"2017-04-01","2017-08-01","2012-04-02",28343,[17],[490],{"intervention":2542,"totalTrials":76,"cells":2543},"Emicizumab subcutaneous",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2550,"PHASE4":2552,"NA":2554},{"trials":2545,"activeCount":80},[],{"trials":2547,"activeCount":80},[],{"trials":2549,"activeCount":80},[],{"trials":2551,"activeCount":80},[],{"trials":2553,"activeCount":80},[],{"trials":2555,"activeCount":80},[2556],{"nctId":2557,"briefTitle":2558,"status":202,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2567},"NCT04805801","The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With\u002FWithout FVIII Inhibitors",[],"2024-07","2025-02","2019-08-28",17,[2565,2566],"Hemophilia A With Inhibitor","Hemophilia A Without Inhibitor",[2542]]